Health

From Sky-High Luxury to Stair-High Challenge: China World Summit Wing, Beijing Elevates Its Urban Lifestyle Destination Positioning with the Return of Vertical Run

BEIJING, Sept. 17, 2025 /PRNewswire/ -- The 2025 China World Summit Wing, Beijing Vertical Run powered to a perfect finish onSeptember 13, 2025 as 1000+ runners conquered 330 meters, 80 floors and over 2,000 steps at the heart of Beijing. Rising above the capital's vibrant CBD, China World Summit...

2025-09-17 09:41 1821

Tapping Into the Trillion-Dollar Healthcare Market: Home Control(1747.HK) will Establish Hong Kong Subsidiary and Build a Global Health Services Ecosystem

HONG KONG, Sept. 17, 2025 /PRNewswire/ -- Home Control (1747.HK), one of the most closely watched small-cap names on theHong Kong market this year, has once again caught investors' attention. After a tenfold rally in the first half of 2025, the Company has unveiled a series of bold strategic move...

2025-09-17 08:00 3629

Genesis MedTech J-VALVE® TF Approved by NMPA, China's First Transfemoral TAVR for Aortic Regurgitation

Clinical data demonstrate low mortality, fewer complications and faster patient recovery with a minimally invasive alternative to open-heart surgery SINGAPORE, Sept. 17, 2025 /PRNewswire/ -- Genesis MedTech's structural heart subsidiary, Suzhou Jiecheng, has received approval fromChina's National...

2025-09-17 07:30 2236

Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

-          ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. -          ASC30 tablet's higher efficacy is supported by its higher oral drug exposures. -          ASC30 is safe and well tolerated with only mild-...

2025-09-17 07:30 1522

EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts

PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that adults with atopic eczema (AE) are significantly more likely to experience suicidal thoughts. As one of the largest global inve...

2025-09-17 06:01 1535

New Scientific Review Highlights β-Lactoglobulin's Dual Benefits for Metabolic and Muscle Health

Emerging evidence positions this dairy protein as a powerful nutritional ingredient – and 21st.BIO's precision fermentation could make it more sustainable than ever. COPENHAGEN, Denmark, Sept. 16, 2025 /PRNewswire/ -- β-Lactoglobulin (BLG), the most abundant whey protein in cow's milk is drawing...

2025-09-16 21:47 1554

Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025

Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC HLMHE session and WBS 2025 Leaders' Dialogue SEOUL, South Korea, Sept. 16, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announc...

2025-09-16 21:00 5071

Over 100 Healthcare Professionals Convene to Explore the Critical Impact of Early Nutrition on Long-Term Brain Development

Mead Johnson Clinical Study Reveals the Sustained Cognitive Benefits of Milk Fat Globule Membrane (MFGM)  Photo download: Link HONG KONG, Sept. 16, 2025 /PRNewswire/ -- Mead Johnson Nutrition Hong Kong ("M...

2025-09-16 19:41 2031

ALCOR Scientific Transforms ESR Testing: Extends Blood Sample Stability from 4 to 28 Hours

Diagnostic Company's iSED Analyzers Deliver Seven-Fold Stability Increase to Improve Accuracy, Efficiency, and Patient Care SMITHFIELD, R.I., Sept. 16, 2025 /PRNewswire/ -- ALCOR Scientific today announced a breakthrough in erythrocyte sedimentation rate (ESR) testing that solves one of the most...

2025-09-16 19:00 1419

ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine

MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its RELIEV-CM Pilot Study. The findings demonstrate sustaine...

2025-09-16 19:00 1331

LA MER DOUBLES DOWN ON MIRACLE BROTH™ WITH NEW BIOENERGETICS RESEARCH PLATFORM AND LANDMARK PARTNERSHIP WITH THE SALK INSTITUTE

THE PLATFORM LAUNCHES WITH 'LA MER GIVES SKIN LIFE' CAMPAIGN & A THREE-YEAR HEALTHY AGING FELLOWSHIP HONG KONG, Sept. 16, 2025 /PRNewswire/ -- La Mer has long been known to provide skin with cellular energy and has remained dedicated to exploring the bioenergetic efficacy of Miracle Broth, from ...

2025-09-16 13:50 1403

Celebrating Cross-Border Partnerships in Healthcare, Asia Medical Week 2025 Convened Leaders in Bali to Strengthen Excellence and Preparedness

BALI, Indonesia, Sept. 16, 2025 /PRNewswire/ -- The Asia Medical Week (AMW) and the Asia Medical Innovation and Development Forum 2025 officially took place fromSeptember 12-13 in Bali with a mission to bring together healthcare leaders from acrossAsia to strengthen cross-border collaboration and...

2025-09-16 13:37 1575

Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery

Potential to reduce the risk of erectile dysfunction and urinary incontinence PERTH, Australia, Sept. 16, 2025 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, Remplir, has been introdu...

2025-09-16 12:13 1675

Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)

HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute myeloid leukemia (A...

2025-09-16 10:27 1440

Chulalongkorn Bariatric and Metabolic Institute (Chula BMI), a One-Stop Service Center for Holistic Obesity Treatment

BANGKOK, Sept. 16, 2025 /PRNewswire/ -- Say goodbye to obesity with the  Chulalongkorn Bariatric and Metabolic Institute (Chula BMI) —King Chulalongkorn Memorial Hospital 's one-stop center for...

2025-09-16 10:00 2168

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025

SAN FRANCISCO and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2025-09-16 09:00 1568

Baxter Launches HEMOPATCH Sealing Hemostat in New Zealand, a Room-Temperature Collagen Pad Approved for Hemostasis and Sealing

DEERFIELD, Ill., Sept. 15, 2025 /PRNewswire/ -- Over the past two decades, surgical techniques have increasingly shifted toward minimally invasive approaches, requiring adapted workflows and skillsets. At the same time, patient complexity has grown, calling for tailored strategies to support safe...

2025-09-16 06:00 1631

LBB Specialties and Imerys Form Specialty Distribution Partnership in North America

NORWALK, Conn., Sept. 16, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader inspecialty chemicals and ingredient distribution inN...

2025-09-16 01:00 1428

Glac Biotech Secures U.S. Food and Drug Administration GRAS Approval for Probiotic Strain CP-9

TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2014588) has been approved with Generally Recognized as Safe (GRAS) status by the U.S. Food and Drug Administr...

2025-09-15 22:00 1826

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

* BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development. * The initiation of the BGE-102 Phase 1 clinical stud...

2025-09-15 21:30 1600
1 ... 47484950515253 ... 872

Week's Top Stories